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Verapamil protects against progression of experimental chronic renal
failure. Chronic administration of verapamil (Ver) decreases nephrocal-
cinosis and tubular ultrastructural abnormalities in the remnant model
of chronic renal disease. In the present study, the effect of chronic Ver
administration on renal function, renal histology and mortality after
subtotal nephrectomy was examined. Fourteen days after staged sub-
total nephrectomy rats were paired according to renal functional
impairment, mean arterial pressure (MAP), and body weight. Rats were
pair fed and received either Ver (0.1 .tgIg sc bid, N = 10) or saline (0.1
ml sc bid, N = 10) for up to 23 weeks. Both members of each pair were
sacrificed shortly before the uremic death of controls. At sacrifice, rats
treated with Ver had a lower serum creatinine (2.29 vs. 2.99 mg/dl, P <
0.05) and a higher creatinine clearance (318 vs. 164 l/min, P < 0.05)
than controls. In a second experiment, survival was superior in rats
treated with Ver than in controls from week seven (P < 0.0025 by week
14). Serum creatinine was higher at week lOin control rats (1.68 vs. 1.10
mg/dl, P < 0.05). MAP was no different between the two groups,
irrespective of the time between Ver administration and the measure-
ment of MAP. Histological damage and nephrocalcinosis were worse,
and renal and myocardial calcium content was higher in controls. In
conclusion, independent of any effect on systematic MAP, chronic
administration of Ver protects against renal dysfunction, histological
damage, nephrocalcinosis and myocardial calcification, and improves
survival in the remnant model of chronic renal disease.
Verapamil (Ver) is effective as a protective agent in various
models of ischemic acute renal failure, including the norepi-
nephrine model of ischemia in the dog [11 and the isolated
perfused rat kidney [2], and this calcium entry blocker may be
beneficial in toxic ARF [3, 4]. The protective effect in ischemic
ARF has been associated with concomitant protection against
mitochondrial Ca2 accumulation and respiratory dysfunction
[1].
Goligorsky and colleagues [5] have shown that chronic Ver
administration is protective against nephrocalcinosis, abnormal
tubular cell Ca2 kinetics and mitochondrial and tubular base-
ment membrane morphological changes, which were found
three weeks after partial nephrectomy in the rat. At this early
stage, however, no changes in renal function had occurred;
there were no differences in serum creatinine in the Ver-treated
and -untreated animals.
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Nephrocalcinosis may well be important in the progression of
chronic renal failure. Phosphate restriction is effective in slow-
ing the progression of various models of chronic renal disease
[6, 7] and this protection is accompanied, and possibly mediated
in part, by a reduction in nephrocalcinosis.
In view of the three week observations on the beneficial effect
of chronic Ver administration on nephrocalcinosis, we have
examined for 15 weeks the effect of Ver on functional deterio-
ration, histological damage, nephrocalcinosis, and survival in
the remnant model of chronic renal failure.
Methods
Two groups of experiments were performed: in the first
(Group I) renal function was studied, and in the second (Group
II) survival and blood pressure were examined. Renal histology
and calcium contents were studied in both groups of experi-
ments.
Renal function (Group I)
Male Sprague—Dawley rats weighing 230 to 340 g were used in
all experiments. One week after removal of 2/3 of the left kidney
and electrocautery of the remaining 1/3, the right kidney was
removed.
For the initial 14 days, post-nephrectomy rats were allowed
to recover on normal rat chow (Wayne Lab-blox) and water ad
libitum. At 14 days they were paired into two groups according
to serum creatinine, creatinine clearance, body weight, and
blood pressure. From day 14 the experimental group (N = 10)
received Ver (0.1 4ug/g body wt) twice daily subcutaneously
(Calcan®, 2.5 mg/ml), while the control group (N = 10) received
normal saline in the same dose.
Rats were housed in individual metabolic cages and were pair
fed on normal rat chow. Urine output was measured daily and
the rats were weighed weekly. Every one to two weeks the rats
were lightly anesthetized with ether and mean arterial pressure
was measured in the tail artery using a 25-gauge needle con-
nected to a Statham transducer (Statham Instruments) and
recorded on a Gilson polygraph. Through the same needle
blood was obtained for the measurement of hematocrit and
plasma creatinine, urea nitrogen, calcium, phosphorus, albu-
min, cholesterol, and triglycerides. Prior to each of these days,
two consecutive 24-hour urine collections were made and the
urine concentrations of protein, calcium, phosphorus, creati-
nine, urea nitrogen, sodium, potassium, and osmolality were
obtained.
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Each rat was sacrificed with its partner at the time of
pre-terminal azotemia of either rat; this was determined by
cessation of eating and confirmed by measurement of plasma
creatinine. Kidney slices and the thoracic aorta were immedi-
ately placed in 10% neutral buffered formalin for light micros-
copy and renal cortical squares in 4% glutaraldehyde in 0.1 M
phosphate buffer, pH 7.3, for electron microscopy. In addition,
pieces of renal cortex (with careful exclusion of tissue scarred
by electrocautery), abdominal aorta, myocardium, lung, liver,
spleen, and dorsal abdominal skeletal muscle were removed for
measurement of Ca2 content. Inulin clearance was measured
by conventional methods in four rats to compare inulin and
creatinine clearance.
Survival and blood pressure (Group II)
In a second group of experiments (Group II), survival was
studied. Rats (N = 22) were prepared, paired and treated in a
method identical to that of the first group. In addition, mean
arterial pressure was measured at varying times after the dose
of Ver or saline to determine if and for how long treatment with
Ver altered mean arterial pressure. The choice of time interval
between Ver administration and mean arterial pressure record-
ing at each two week period was random and varied between 0
and 5-1/2 hours.
Histology
At sacrifice, the aorta and portions of kidney were fixed in
neutral buffered formalin. Histologic sections were stained with
hematoxylin (H) and eosin (E), and by Von Kossa stain for
calcium. Kidney sections were also examined following prepa-
ration with PAS and trichrome stains. Histologic sections were
coded so that the observer did not know which tissues were
from control rats and which were from Ver-treated rats. Aortic
and renal calcification was graded semiquantitatively from 0 to
3+. The percentage of glomeruli with global or segmental
sclerosis was determined; <40% abnormal glomeruli was des-
ignated 1 + ; 40 to 60% was 2+; and >60% was 3+. The severity
of tubulointerstitial disease was graded semiquantitatively from
1+ (mild) to 3+ (severe). A renal "severity score" was deter-
mined for each rat by adding the scores for tissue calcification,
glomerular involvement, and tubulointerstitial disease.
For comparison of histology (and calcium content) the rats
from both groups were used. In Group II, all of the rats were
examined at week 15.
Chemical analysis
Creatinine and urea nitrogen were measured by automated
techniques using a Beckman-2 creatinine and Beckman-2 urea
analyzer (Beckman Instruments Inc., Fullerton, California,
USA). Plasma cholesterol and triglycerides were measured by
enzymatic methods [8, 91, albumin by a colorimetric method
[101, sodium and potassium by flame photometry (Instrumenta-
tion Labs., Inc., Cidra, Puerto Rico), osmolality by an Ad-
vanced osmometer (model 3R, Advanced Instruments, Inc.,
Needham Heights, Massachusetts, USA), calcium by color-
imetric orthocresophthalein complexone [111, phosphorus by
colorimetric phosphomolybdate [121, urinary protein by tn-
chloroacetic acid precipitation [13], and inulin by an autoana-
lyzer method. Tissue calcium content was determined by
Table 1. Blood pressure, weight and biochemical parameters
of pairing (day 14) in Group I experiments
at time
Verapamil Control
Treatment (N = 10) (N = 10) P value
Plasma creatimne mg/dl 1.89 0.22 1.73 0.16
Plasma urea nitrogen mg/dl 78.1 9.9 74.9 7.7
Creatinine clearance 1.d/min 91 20 64 22
Proteinuria mg/day 73.9 16.4 102.4 31.0
Mean arterial pressure mm Hg 93.5 4.7 103.2 10.7







atomic absorption spectrophotometnic methodology (model
290B, Perkin—Elmer, Pasadena, California, USA).
Statistical analysis
Comparisons between control and experimental rats were
made using the Student's unpaired t-test and chi-squared anal-
ysis. Survival was analyzed using the life table method [14]. All
results are expressed as the mean standard error of mean.
Results
Initial rena/function and body weight
In both Group I (renal function) and Group II (survival and
blood pressure) studies there were no significant differences in
plasma creatinine, plasma urea nitrogen, creatinine clearance,
mean arterial pressure, proteinuria and body weight between
the Ver and saline—treated groups at the time of pairing (day 14).
The values for the Group I studies are given in Table 1.
Nutrition
In the Group I studies, there were no significant differences
between control and experimental groups in weight gain (Fig. 1)
and urinary excretion of water (Fig. 2), sodium, potassium, and
total solutes, as expected with pair feeding.
Biochemical parameters
In the Group I studies, treatment with Ver afforded protec-
tion against the deterioration in renal function seen in these












Fig. 1. Progressive weight gain in rats treated with verapamil (closed
circles) or saline (open circles). Nephrectomy was performed two
weeks before treatment was commenced. Mean SEM.
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Fig. 3. Mean arterial blood pressure (MAP) of Group I! rats treated
____________________________________________________
with verapamil () or saline (E), taken at varying times after the last
—1 0 2 4 6 8 10 12 14 dose of verapamil. There were no significant differences between the
Time, wks MAP of verapamil—treated rats or controls. Mean SEM.




Control(N = 9) P value
Plasma creatinine mg/dl 2.29 0.17 2.99 0.26 <0.05
Plasma urea nitrogen mg/dl,
N = 8 100 14 150 16 <0.05
Creatinine clearance pi/min 318 63 164 41 <0.05
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normal renal function, and his partner, were excluded from
analysis. In eight out of the nine remaining pairs of rats, Ver had
an obvious protective effect (chi-square analysis, P < 0.0025).
These significant differences can be seen also when indices of
renal function (Table 2) are examined. All tests of renal function
were significantly worse in the control rats. In four rats terminal
inulin clearance (C1) was compared to simultaneous terminal
creatinine clearance (Ccr), and the ratio of Cin/Cr was 0.92
0.20.
Protein excretion increased progressively throughout the
study in each rat and no differences in proteinuria could be
demonstrated with treatment (mean proteinuria 294 67 vs.
354 42 mg/24 hr, Ver vs. control). Similarly, no effect of Ver
on the decrease in hematocrit or increase in triglycerides and
cholesterol was seen. Ver-treated animals at week 10 had a
numerically, but not significantly lower serum phosphorus (6.76
0.49 vs. 11.63 2.37, NS); no consistent effects on serum
calcium, urinary calcium or urinary phosphorus were seen.
Mean arterial pressure
As shown in Figure 3, mean arterial pressure was taken in the
Group II experiments at varying times (0 to 5-1/2 hr) after the
last dose of Ver or saline; one reading was taken for each rat
every two weeks. There was no significant difference between
the control and Ver-treated groups. An equal number of rats
(6/11) from both groups had readings of >150mm Hg on one or
more occasions. Thus, the protective effect of Ver in the
Weeks after Nephrectomy
Fig. 4. Cumulative survival of Group II rats treated with verapamil
(closed circles) or saline (open circles). Symbols are (*) P < 0.05; (**)
P < 0.005.
present study appears to be independent of an effect on sys-
temic mean arterial pressure.
Survival
In the Group II experiments, one rat in the Ver group died at
week five with a serum creatinine of 1.0 mg/dl; another Ver-
treated rat died at week 14 with a large staghorn calculus—caus-
ing obstruction. All rats have been included in the survival table
(Fig. 4). At week seven, cumulative survival was worse in the
control group (64% vs. 100% in Ver-treated rats, P < .025). The
difference continued until the completion of the study at week
15 (19% vs. 71%, P <0.005).
Histology
Abnormal glomeruli were enlarged and characterized by
segmental and global sclerosis, hyalinosis, and adhesions of the
tuft to Bowman's capsule. Tubules varied from histologically
normal to markedly dilated and tortuous. Some dilated tubules
contained casts and had flattened epithelium. There were vary-
ing degrees of interstitial fibrosis with tubular atrophy and an
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Table 3. Calcium contents in nmol/mg dry weight


















content of liver, spleen and muscle was no different between the
two groups.
Discussion
The cost of renal replacement therapy to the community and
the patient [15] and the quality of life of patients receiving this
therapy [16] argue for prevention rather than treatment of
end—stage renal failure. There are several non-specific mea-
sures, both dietary and pharmacological, currently available or
under investigation that appear to slow the otherwise relentless
progression of chronic renal failure. Dietary manipulations
include restriction of protein [171, phosphate [61, and perhaps
calories [18], acid [19], and lipid [18]. Pharmacological inter-
ventions are of less proven benefit and include systemic [20, 21]
and glomerular [22, 231 antihypertensive agents, dopamine
agonists [24], prostaglandin inhibitors [25], and anticoagulants
[26, 27].
Studies by Goligorsky and colleagues [5] have shown that yet
another approach may be of value in prevention of progression
of chronic renal failure. In their investigations the chronic
administration of the calcium entry blocker, Ver, was shown to
prevent calcium accumulation in tubular cells and basement
membrane, correct abnormal cellular calcium kinetics as well as
prevent mitochondrial and tubular basement membrane ultra-
structural changes. These observations with Ver were exciting
since calcium entry blockers have recently been shown to be
protective against acute ischemic [1, 2] and nephrotoxic [3, 4]
injury. These findings, therefore, suggested that cellular epithe-
hal and vascular uptake of calcium might be involved in both
acute and chronic renal injury. The studies of Goligorsky et al
[5], however, involved observations for only three weeks, a
time period too short for functional deterioration in this sub-
total nephrectomy model of chronic renal failure.
The present studies were therefore undertaken to extend to
15 weeks the observations of Goligorsky et al with the purpose
of examining the effect of chronic Ver administration on renal
functional deterioration and survival in this model of experi-
mental chronic renal failure. The results demonstrated that
chronic Ver significantly attenuated the rate of deterioration of
renal function. The protection of renal function occurred de-
spite the absence of any observable effect of verapamil on
proteinuria, suggesting that proteinuria and progressive deteri-
oration of renal function are not related directly in this model of
chronic renal disease. In addition, the protective effect of
chronic Ver treatment was associated with a significant de-
crease in calcium content of the kidney at the time of sacrifice,
an observation supported by the histological study of the
kidney, It is of interest that, unlike the studies of Goligorsky et
al in which tubular ultrastructural damage was prevented by
Ver administration, in the present study histological protection
7 r















Fig. 5. Semi-quantitative score for glomerular and tubulo-interstitial
histological damage. Each component is scored on a scale of 0 to 3.
Total renal score represents the mean sum of scores for glomerular and
tubulo-interstitial damage and nephrocalcinosis. Mean SEM. Symbols








Fig. 6. Renal calcium accumulation as assessed semi-quantitatively at
histology (score) and quantitatively by tissue analysis. Mean SEM.
stitial, either in the form of small nodular masses or linear
deposits along tubular basement membranes. Aortic calcifica-
tion varied from fine, powdery calcific deposits, apparently
within smooth muscle cells, to dense calcification of elastic
fibers and heavy calcific deposits disrupting and replacing
smooth muscle.
When assessed in a blind semi-quantitative manner, glomer-
ular damage, nephrocalcinosis and overall severity of renal
damage were significantly worse in control animals (Figs. 5 and
6). Aortic calcification appeared worse in control rats but this
did not reach statistical significance.
Calcium content
The mean calcium content was significantly higher in control
rats in the kidney and myocardium (Fig. 6, Table 3). Although
mean calcium content was higher in the lung and aorta in
control rats, this did not reach statistical significance. Calcium
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was limited to glomerular damage and nephrocalcinosis. These
findings, therefore, extended the three week observations of
Goligorsky et al [5], thus suggesting that prevention of tissue
calcium accumulation may be a determinant of the protective
effect of Ver in chronic renal failure. Renal tissue calcification is
also common in end—stage renal failure in humans [28] and in
diseased kidney even before serum creatinine has risen [291,
and nephrocalcinosis has been observed in both immunological
[7] and non-immunological [61 models of chronic renal failure.
In this regard, it is important to emphasize that the protective
effect of phosphate restriction has been shown to be associated
with diminished renal tissue calcification in both immunological
[7] and non-immunological [6] models of chronic renal failure.
Taken together, the present and previous results are compatible
with increased cellular calcium uptake as a potential factor
involved in both acute and chronic renal injury. However, as
has been argued previously [18], this does not exclude cellular
calcium accumulation secondary to cell death. The enhanced
calcium uptake of acute and chronic renal injury may cause
cellular damage by several mechanisms including: 1) mitochon-
drial injury secondary to calcium overload; 2) membrane injury
secondary to activation of phospholipases; and 3) enhanced
oxygen radical formation. Recent in vivo experiments have
confirmed that the calcium entry blockers Ver and nifedipine
may afford cellular protection by diminishing cellular calcium
uptake. These calcium entry blockers have been shown to
protect against anoxic cell injury in cultured proximal and
cortical collecting tubules of rabbits [30] and in suspensions of
rat proximal tubules [31].
The calcium membrane blockers, Ver and nifedipine, also
have been shown to block the systemic pressor response and
intrarenal vasoconstriction of angiotensin, norepinephrine and
vasopressin [32], to lower systemic blood pressure in normal
and hypertensive animals [33, 34], and have been used to treat
hypertension in man. In this regard, there can be little doubt
that control of hypertension may exert a beneficial effect
relative to progression of renal disease in both man [35—37] and
experimental animals [20, 21] with chronic renal failure. How-
ever, in the present study the beneficial effect of Ver was
demonstrated to be independent of differences in blood pres-
sure, suggesting that factors other than systemic hypertension
were important in determining the progressive deterioration of
renal function. An enhanced solute diuresis has been shown to
exert protection in experimental renal failure, and Ver not only
increases renal blood flow but also causes a solute diuresis [33,
38]. However, in the present study chronic subcutaneous Ver
administration was not associated with differences in solute
excretion as compared to the control animals.
The other major pathway whereby Ver may exert its protec-
tive effect in this model of chronic renal failure is by altering
intrarenal hemodynamics. There is recent evidence that con-
verting enzyme inhibitors may protect against glomerular injury
by diminishing the glomerular transcapillary hydraulic—pressure
gradient independent of changes in systemic blood pressure [22,
39]. In this regard, Ver has been shown to block both the effect
of angiotensin on glomerular microcirculation [40] and mesan-
gial uptake of macromolecules [41].
Thus, in summary, chronic Ver treatment has been shown to
retard the progression of chronic renal failure in the partially
nephrectomized rat independent of an effect on systemic blood
pressure. This protective effect of Ver was shown to be
associated with diminished renal tissue calcium as assessed
histologically and as measured by atomic absorption spectro-
photometric methodology. Not only was there less functional
and morphological damage observed in the Ver-treated animals,
but a significantly improved survival also occurred. The effect
of Ver on tissue calcium uptake, as well as a potential effect on
intrarenal hemodynamics, appear most likely to mediate this
effect of Ver on chronic renal failure. Thus, calcium entry
blockers such as Ver may afford protection not only in acute
renal failure [1], but also may attenuate progression of chronic
renal disease.
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